| Dr Jil A Beaupain, DPM | |
|
92 Woodbridge Corner Rd, Sherman, ME 04776-3330 | |
| (207) 532-9790 | |
| (207) 532-6550 |
| Full Name | Dr Jil A Beaupain |
|---|---|
| Gender | Female |
| Speciality | Podiatry |
| Experience | 34 Years |
| Location | 92 Woodbridge Corner Rd, Sherman, Maine |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427116300 | NPI | - | NPPES |
| POD229 | Other | ME | STATE OF MAINE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213EP1101X | Podiatrist - Primary Podiatric Medicine | SC003477L (Pennsylvania) | Secondary |
| 213ES0131X | Podiatrist - Foot Surgery | POD229 (Maine) | Primary |
| Provider Name | Millinocket Regional Hospital |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1275646150 PECOS PAC ID: 3779491212 Enrollment ID: O20040523000014 |
News Archive
The husband snores. The wife nudges him to flip over. Both wake up feeling grouchy the next morning. It's a common occurrence that may have more of an impact on the marriage than most couples think.
Among obese individuals, having bariatric surgery was associated with a reduced long-term incidence of cardiovascular deaths and events such as heart attack and stroke, according to a study in the January 4 issue of JAMA.
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration in cardiovascular diseases, central nervous system injuries, ophthalmic indications and dermal wounds, announced the pricing of its previously announced underwritten public offering of 11,500,000 units of its securities at a public offering price of $0.41 per unit.
The recent US Food and Drug Administration (FDA) approval of aducanumab – which has the potential to treat Alzheimer's disease – may provide a proof of concept that can be rapidly improved upon, writes Dennis Selkoe in this Perspective.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jil A Beaupain, DPM Po Box 130, Sherman, ME 04776-0130 Ph: (207) 532-9790 | Dr Jil A Beaupain, DPM 92 Woodbridge Corner Rd, Sherman, ME 04776-3330 Ph: (207) 532-9790 |
News Archive
The husband snores. The wife nudges him to flip over. Both wake up feeling grouchy the next morning. It's a common occurrence that may have more of an impact on the marriage than most couples think.
Among obese individuals, having bariatric surgery was associated with a reduced long-term incidence of cardiovascular deaths and events such as heart attack and stroke, according to a study in the January 4 issue of JAMA.
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration in cardiovascular diseases, central nervous system injuries, ophthalmic indications and dermal wounds, announced the pricing of its previously announced underwritten public offering of 11,500,000 units of its securities at a public offering price of $0.41 per unit.
The recent US Food and Drug Administration (FDA) approval of aducanumab – which has the potential to treat Alzheimer's disease – may provide a proof of concept that can be rapidly improved upon, writes Dennis Selkoe in this Perspective.
› Verified 4 days ago